Abstract:Immune evasion contributes to cancer growth and progression. Cancer cells have the ability to activate different immune checkpoint pathways that harbor immunosuppressive functions. The programmed death protein 1 (PD-1) and programmed cell death ligands (PD-Ls) are considered to be the major immune checkpoint molecules. The interaction of PD-1 and PD-L1 negatively regulates adaptive immune response mainly by inhibiting the activity of effector T cells while enhancing the function of immunosuppressive regulatory T cells (Tregs), largely contributing to the maintenance of immune homeostasis that prevents dysregulated immunity and harmful immune responses. However, cancer cells exploit the PD-1/PD-L1 axis to cause immune escape in cancer development and progression. Blockade of PD-1/PD-L1 by neutralizing antibodies restores T cells activity and enhances anti-tumor immunity, achieving remarkable success in cancer therapy. Therefore, the regulatory mechanisms of PD-1/PD-L1 in cancers have attracted an increasing attention. This article aims to provide a comprehensive review of the roles of the PD-1/PD-L1 signaling in human autoimmune diseases and cancers. We summarize all aspects of regulatory mechanisms underlying the expression and activity of PD-1 and PD-L1 in cancers, including genetic, epigenetic, post-transcriptional and post-translational regulatory mechanisms. In addition, we further summarize the progress in clinical research on the antitumor effects of targeting PD-1/PD-L1 antibodies alone and in combination with other therapeutic approaches, providing new strategies for finding new tumor markers and developing combined therapeutic approaches.

Current Insight into the Regulation of PD-L1 in Cancer

Regulation of PD-1 in T cells for cancer immunotherapy

Regulation of PD-L1 expression in the tumor microenvironment

Regulation of PD-L1: Emerging Routes for Targeting Tumor Immune Evasion

The Nuclear Transportation of PD-L1 and the Function in Tumor Immunity and Progression

Regulatory mechanisms of PD-1/PD-L1 in cancers

Regulation mechanism of PD-L1 expression and its effect on antitumor immune responses

PD-1/PD-L1 pathway: current researches in cancer.

The opportunities and challenges in immunotherapy: Insights from the regulation of PD-L1 in cancer cells.

The emerging roles of PD-L1 subcellular localization in tumor immune evasion

PD-1 regulation in immune homeostasis and immunotherapy

Tumor Immune Checkpoints and Their Associated Inhibitors

Regulatory mechanisms of immune checkpoints PD-L1 and CTLA-4 in cancer

Generation, secretion and degradation of cancer immunotherapy target PD-L1

PD-1 and its ligands are important immune checkpoints in cancer

Role of the tumor microenvironment in PD-L1/PD-1-mediated tumor immune escape

Comprehensive insights into the effects and regulatory mechanisms of immune cells expressing programmed death-1/programmed death ligand 1 in solid tumors

A snapshot of the PD-1/PD-L1 pathway

Emerging therapeutic frontiers in cancer: insights into posttranslational modifications of PD-1/PD-L1 and regulatory pathways

Extracellular and nuclear PD-L1 in modulating cancer immunotherapy

The generation of PD-L1 and PD-L2 in cancer cells: From nuclear chromatin reorganization to extracellular presentation